Gary Sender - 20 Nov 2025 Form 4 Insider Report for iBio, Inc. (IBIO)

Reporting relationship
Director
Issuer ticker
IBIO
Reported as of
20 Nov 2025
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
24 Nov 2025, 16:08:30 UTC
Prior SEC filing
20 Jun 2025
Next SEC filing
18 May 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Marc Banjak, Attorney-in-fact

Key filing fact

Gary Sender filed Form 4 for iBio, Inc. (IBIO) on 24 Nov 2025.

Key facts

  • This page summarizes Gary Sender's Form 4 filing for iBio, Inc. (IBIO).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 24 Nov 2025, 16:08.

Change

  • Previous filing in this sequence was filed on 20 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001659085 Primary reporting owner

Sender Gary

Relationship
Director
Address
C/O IBIO, INC., 11750 SORRENTO VALLEY, ROAD, SUITE 200, SAN DIEGO
Signature
/s/ Marc Banjak, Attorney-in-fact
Signature date
24 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IBIO transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+13,500
Change %
Price
$0.000000
Shares after
13,500
Date
20 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
13,500
Exercise price
$1.00
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .